Goodfellow John A, Willison Hugh J
aNeuroimmunology Laboratory, Queen Elizabeth University Hospital bInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Curr Opin Neurol. 2016 Oct;29(5):572-80. doi: 10.1097/WCO.0000000000000361.
There has been a recent renewed interest in the prevalence of antiglycolipid antibodies and their associations with specific clinical phenotypes in Guillain-Barré syndrome. Recent reports have sought to confirm and expand the antibody-phenotype associations of antiganglioside antibodies, antiganglioside-complex antibodies, and antiglycolipid-complex antibodies in the various acute immune-mediated neuropathies. This is a rapidly developing field with technical advances in assay methodology, which have resulted in numerous new putative antibody-phenotype associations.
Antibodies against single ganglioside species remain the most established serological marker of Guillain-Barré syndrome and its myriad clinical variants. Antibodies against combinations of gangliosides, ganglioside-complex antibodies, detected by the ELISA method have emerged as putative markers of certain clinical features or pathological subtypes, specifically acute motor axonal neuropathy, but do not seem to greatly increase the diagnostic sensitivity of antibody testing as most also react with single ganglioside species. The novel assay method of the combinatorial glycoarray allows high-throughput detection of antibodies recognizing combinations of gangliosides and other glycolipids and early studies suggest it identifies antibody-phenotype associations in addition to significantly increasing the sensitivity of serological testing, including for the acute inflammatory demyelinating polyneuropathy variant.
Antibodies against single ganglioside species remain diagnostically useful in routine clinical practice. Antibodies against ganglioside complexes, or gangliosides and other glycolipid complexes, are emerging as useful markers of various clinic features and pathological subtypes; however, the precise associations remain to be fully delineated and confirmed. The antibody-complex detection methods are rapidly evolving but in most centres are not yet available in routine clinical practice.
近期,人们对格林-巴利综合征中抗糖脂抗体的患病率及其与特定临床表型的关联重新产生了兴趣。最近的报告试图证实并扩展抗神经节苷脂抗体、抗神经节苷脂复合物抗体和抗糖脂复合物抗体在各种急性免疫介导性神经病中的抗体-表型关联。这是一个快速发展的领域,检测方法有技术进步,导致了众多新的假定抗体-表型关联。
针对单个神经节苷脂种类的抗体仍然是格林-巴利综合征及其众多临床变异型最确定的血清学标志物。通过酶联免疫吸附测定(ELISA)方法检测到的针对神经节苷脂组合的抗体,即神经节苷脂复合物抗体,已成为某些临床特征或病理亚型的假定标志物,特别是急性运动轴索性神经病,但似乎并没有显著提高抗体检测的诊断敏感性,因为大多数此类抗体也与单个神经节苷脂种类发生反应。组合糖芯片这种新的检测方法能够高通量检测识别神经节苷脂和其他糖脂组合的抗体,早期研究表明,它除了能显著提高血清学检测的敏感性(包括对急性炎症性脱髓鞘性多发性神经病变异型的检测)外,还能识别抗体-表型关联。
针对单个神经节苷脂种类的抗体在常规临床实践中仍具有诊断价值。针对神经节苷脂复合物或神经节苷脂与其他糖脂复合物的抗体正逐渐成为各种临床特征和病理亚型的有用标志物;然而,确切的关联仍有待全面描述和证实。抗体复合物检测方法正在迅速发展,但在大多数中心尚未应用于常规临床实践。